A review of the preclinical antitumor activity and toxicology of L-asparaginase derived from E. coli.
D000818:Animals; D001215:Asparaginase / Q000627:therapeutic use* / Q000633:toxicity; D002460:Cell Line; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D004926:Escherichia coli / Q000201:enzymology; D006168:Guinea Pigs; D007928:Lethal Dose 50; D007942:Leukemia, Experimental / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008253:Macaca mulatta; D051379:Mice; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D011817:Rabbits; D051381:Rats; D012513:Sarcoma, Experimental / Q000188:drug therapy
D001215:Asparaginase